Hanwha Pharm seeking injunction trial to invalidate cancellation of product license of Livial

Following the Korea Food and Drug Administration's disposition to cancel the product license of Livial on November 22 due to less content of active ingredient in some of bottle products, Hanwha Pharm has recently raised to the Seoul District Court an injunction trial against the KFDA to invalidate cancellation of the product license and expect that the court may accept the offer within the next...